MedTech Dive November 4, 2024
Cortex adds to Boston Scientific’s electrophysiology portfolio amid treatment shifts in the space driven by new pulsed field ablation devices.
Dive Brief:
- Boston Scientific continued its active M&A year with an agreement to buy privately held Cortex for an undisclosed amount.
- Cortex develops diagnostic mapping technology to detect potential signs and triggers of atrial fibrillation (AFib) outside of the pulmonary veins. In the announcement Monday, Boston Scientific pitched the company’s technology as a tool for physicians to develop ablation procedure strategies in complex AFib cases.
- Boston Scientific expects to close the deal in the first half of 2025. It said the purchase will have an immaterial impact on adjusted earnings per share next year.
Dive Insight:
The Cortex...
Today's Sponsors
Today's Sponsor